Inside the research
Privia Health Group, Inc.
PRVA Research profile · latest available data
Price overview
$19.71
▲ +0.32 (+1.7%)
| 52w hi | $28.10 |
|---|---|
| 52w lo | $19.10 |
| Vol | 1.39M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.19
| Short | -0.47 |
|---|---|
| Medium | -0.13 |
| Long | +0.24 |
computed 2026-09-27
Key fundamentals
Privia Health Group, Inc.
Healthcare · Health Information Services
| Market cap | $2.52B |
|---|---|
| Enterprise value | $2.17B |
| Trailing P/E | 89.59x |
| Forward P/E | 18.58x |
| EV / EBITDA | 38.11x |
| P / S (ttm) | 1.07x |
| Profit margin | 1.2% |
| Return on equity | 4.3% |
| Revenue growth | +21.4% |
| Earnings growth | +250.0% |
| Debt / equity | 1.04 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.30 | |
| Sector | +0.08 | |
| Technical | -0.39 | |
| Earnings | +0.00 | |
| Sentiment | +0.12 |
macro × 1.00 · 2026-09-27
Business overview
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
Risk Metrics
| Beta vs SPX | 0.64 |
|---|---|
| Corr SPX | 0.30 |
| Annual vol | 33.9% |
| Annual ret | +8.2% |
| Sharpe | 0.24 |
| Max DD | -32.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-07-07 | Officer / Director Change | read |
| 2026-05-22 | Shareholder Vote | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2025-12-08 | Other Material Event | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-10-28 | Other Material Event | read |
| 2025-09-23 | Other Material Event | read |
| 2025-08-29 | Reg FD Disclosure, Exhibits | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-07-08 | Officer / Director Change, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | Mountcastle David | EVP & Chief Financial Off | Sell | 21.27K | $588.68K |
| 2026-07-07 | Mountcastle David | EVP & Chief Financial Off | Sell | 600 | $16.54K |
| 2026-07-06 | Morris Matthew Shawn | Sell | 53.72K | $1.46M | |
| 2026-07-06 | Morris Matthew Shawn | Option exercise | 53.72K | $107.44K | |
| 2026-07-02 | Mountcastle David | EVP & Chief Financial Off | Sell | 24.73K | $680.18K |
| 2026-07-02 | Morris Matthew Shawn | Option exercise | 59.04K | $118.07K | |
| 2026-07-02 | Morris Matthew Shawn | Sell | 59.04K | $1.61M | |
| 2026-07-01 | Morris Matthew Shawn | Option exercise | 82.67K | $165.35K | |
| 2026-07-01 | Morris Matthew Shawn | Sell | 45.63K | $1.21M | |
| 2026-07-01 | Morris Matthew Shawn | Sell | 37.04K | $997.51K |
Flow & Concentration
| Insider 180d net | -$12.19M |
|---|---|
| Insider buys / sells | 0 / 11 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 98.3% |
| HHI | 5,108 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $330.59M | 12.85M |
| State Street Corp | $126.23M | 4.91M |
| Renaissance Technologies | $16.28M | 632.70K |
| Capital Research / Capital World | $7.34M | 285.21K |
| Millennium Management | $6.90M | 268.32K |
| AQR Capital Management | $6.58M | 255.61K |
| Citadel Advisors | $1.98M | 77.14K |
| T. Rowe Price Group | $4.42K | 171.90K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2021–2025 · 5 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Operating income | $16.98M | -18.2% | |
| Net income | $14.38M | +74.5% | |
| Cash from ops | $163.40M | +31.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $19.36 | $19.88 | $19.28 | $19.71 | 1.39M |
| Sep 24 | $19.10 | $19.40 | $18.92 | $19.39 | 1.48M |
| Sep 23 | $19.39 | $19.53 | $18.98 | $19.10 | 980.10K |
| Sep 22 | $19.53 | $19.90 | $19.42 | $19.46 | 1.09M |
| Sep 21 | $19.86 | $20.45 | $19.42 | $19.54 | 980.20K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →